Literature DB >> 29953670

Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry.

William D Leslie1, Helena Johansson2,3, Eugene V McCloskey3, Nicholas C Harvey4,5, John A Kanis2,3, Didier Hans6.   

Abstract

Type 2 diabetes is a risk factor for fracture independent of FRAX (fracture risk assessment) probability. We directly compared four proposed methods to improve the performance of FRAX for type 2 diabetes by: (1) including the rheumatoid arthritis (RA) input to FRAX; (2) making a trabecular bone score (TBS) adjustment to FRAX; (3) reducing the femoral neck T-score input to FRAX by 0.5 SD; and (4) increasing the age input to FRAX by 10 years. We examined major osteoporotic fractures (MOFs) and hip fractures (HFs) over a mean of 8.3 years observation among 44,543 women and men 40 years of age or older (4136 with diabetes) with baseline lumbar spine and hip DXA from 1999 through 2016. Controlled for unadjusted FRAX probability, diabetes was associated with an increased risk for MOFs and HFs. All four FRAX adjustments attenuated the effect of diabetes, but a residual effect of diabetes was seen on MOF risk after TBS adjustment, and on HF risk after the RA and TBS adjustments. Among those with diabetes, unadjusted FRAX risk underestimated MOF (observed/predicted ratio 1.15; 95% CI, 1.03 to 1.28), but this was no longer significant after applying the diabetes adjustments. HF risk was more severely underestimated (observed/predicted ratio 1.85; 95% CI, 1.51 to 2.20) and was only partially corrected with the diabetes adjustments (still significant for the RA and TBS adjustments). Among those with diabetes, there was moderate reclassification based upon a fixed MOF cut-off of 20% (4.1% to 7.1%) or fixed HF cut-off of 3% (5.7% to 16.5%). Net reclassification improvement increased for MOF with each of the diabetes adjustments (range 3.9% to 5.6% in the diabetes subgroup). In conclusion, each of the proposed methods for addressing limitations in the ability of FRAX to assess fracture risk in individuals with diabetes was found to improve performance, though no single method was optimal in all settings.
© 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research.

Entities:  

Keywords:  DIABETES; DXA; FRACTURE RISK ASSESSMENT; FRAX; OSTEOPOROSIS; TRABECULAR BONE SCORE

Mesh:

Year:  2018        PMID: 29953670      PMCID: PMC6193547          DOI: 10.1002/jbmr.3538

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  43 in total

1.  Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system.

Authors:  N P Roos; E Shapiro
Journal:  Med Care       Date:  1999-06       Impact factor: 2.983

Review 2.  Type 2 diabetes and bone.

Authors:  William D Leslie; Mishaela R Rubin; Ann V Schwartz; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-09-28       Impact factor: 6.741

3.  Competing mortality and fracture risk assessment.

Authors:  W D Leslie; L M Lix; X Wu
Journal:  Osteoporos Int       Date:  2012-06-27       Impact factor: 4.507

Review 4.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide.

Authors:  Maarten J G Leening; Moniek M Vedder; Jacqueline C M Witteman; Michael J Pencina; Ewout W Steyerberg
Journal:  Ann Intern Med       Date:  2014-01-21       Impact factor: 25.391

5.  FRAX underestimates fracture risk in patients with diabetes.

Authors:  Lora M Giangregorio; William D Leslie; Lisa M Lix; Helena Johansson; Anders Oden; Eugene McCloskey; John A Kanis
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

6.  Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos.

Authors:  L-A Fraser; L Langsetmo; C Berger; G Ioannidis; D Goltzman; J D Adachi; A Papaioannou; R Josse; C S Kovacs; W P Olszynski; T Towheed; D A Hanley; S M Kaiser; J Prior; S Jamal; N Kreiger; J P Brown; H Johansson; A Oden; E McCloskey; J A Kanis; W D Leslie
Journal:  Osteoporos Int       Date:  2010-12-16       Impact factor: 4.507

7.  Trabecular Bone Score (TBS) and TBS-Adjusted Fracture Risk Assessment Tool are Potential Supplementary Tools for the Discrimination of Morphometric Vertebral Fractures in Postmenopausal Women With Type 2 Diabetes.

Authors:  Yong Jun Choi; So Young Ock; Yoon-Sok Chung
Journal:  J Clin Densitom       Date:  2016-04-27       Impact factor: 2.617

Review 8.  Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice.

Authors:  N C Harvey; C C Glüer; N Binkley; E V McCloskey; M-L Brandi; C Cooper; D Kendler; O Lamy; A Laslop; B M Camargos; J-Y Reginster; R Rizzoli; J A Kanis
Journal:  Bone       Date:  2015-05-16       Impact factor: 4.398

9.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

Review 10.  MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.

Authors:  F S Hough; D D Pierroz; C Cooper; S L Ferrari
Journal:  Eur J Endocrinol       Date:  2015-11-04       Impact factor: 6.664

View more
  25 in total

1.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2018-10-15       Impact factor: 4.507

Review 2.  Falls and Fractures in Diabetes-More than Bone Fragility.

Authors:  Nicklas Højgaard Rasmussen; Jakob Dal
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

3.  Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.

Authors:  Richard H Lee; Richard Sloane; Carl Pieper; Kenneth W Lyles; Robert A Adler; Courtney Van Houtven; Joanne LaFleur; Cathleen Colón-Emeric
Journal:  J Bone Miner Res       Date:  2019-10-09       Impact factor: 6.741

4.  Major osteoporosis fracture prediction in type 2 diabetes: a derivation and comparison study.

Authors:  Xiao-Ke Kong; Zhi-Yun Zhao; Deng Zhang; Rui Xie; Li-Hao Sun; Hong-Yan Zhao; Guang Ning; Wei-Qing Wang; Jian-Min Liu; Bei Tao
Journal:  Osteoporos Int       Date:  2022-05-18       Impact factor: 5.071

Review 5.  UK clinical guideline for the prevention and treatment of osteoporosis.

Authors:  Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston
Journal:  Arch Osteoporos       Date:  2022-04-05       Impact factor: 2.879

Review 6.  A brief history of FRAX.

Authors:  John A Kanis; Helena Johansson; Nicholas C Harvey; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2018-10-31       Impact factor: 2.617

Review 7.  Fracture prediction, imaging and screening in osteoporosis.

Authors:  Nicholas R Fuggle; Elizabeth M Curtis; Kate A Ward; Nicholas C Harvey; Elaine M Dennison; Cyrus Cooper
Journal:  Nat Rev Endocrinol       Date:  2019-09       Impact factor: 43.330

Review 8.  Approaches to Fracture Risk Assessment and Prevention.

Authors:  Sanford Baim; Robert Blank
Journal:  Curr Osteoporos Rep       Date:  2021-02-01       Impact factor: 5.096

9.  Sex-specific associations of serum insulin-like growth factor-1 with bone density and risk of fractures in Chinese patients with type 2 diabetes.

Authors:  F Lv; X Cai; R Zhang; L Zhou; X Zhou; X Han; L Ji
Journal:  Osteoporos Int       Date:  2021-01-07       Impact factor: 4.507

10.  Correlation of Osteoporosis in Patients With Newly Diagnosed Type 2 Diabetes: A Retrospective Study in Chinese Population.

Authors:  Yuhua Wen; Huijuan Li; Xiaoya Zhang; Peipei Liu; Jing Ma; Liya Zhang; Keqin Zhang; Lige Song
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-14       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.